Vor Biopharma (VOR) Depreciation & Amortization (CF) (2020 - 2026)
Vor Biopharma (VOR) reported Depreciation & Amortization (CF) of $28000.0 for Q1 2026, down 96.5% year-over-year from $800000.0 in Q1 2025, and down 22.22% quarter-over-quarter from $36000.0 in Q4 2025.
Vor Biopharma (VOR) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $28000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $28000.0, down 96.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (down 37.41% YoY), and the FY2025 annual result was $2.9 million, down 17.14% from the prior year.
- Depreciation & Amortization (CF) retreated to $28000.0 in Q1 2026 per VOR's latest filing, from $36000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $2.1 million in Q2 2025 and troughed at -$36000.0 in Q3 2025.
- A 5-year average of $736647.1 and a median of $837000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) jumped 200.0% in 2022, then slumped 104.0% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $632000.0 in 2022, then soared by 42.41% to $900000.0 in 2023, then fell by 11.11% to $800000.0 in 2024, then tumbled by 95.5% to $36000.0 in 2025, then retreated by 22.22% to $28000.0 in 2026.
- Business Quant data shows VOR's Depreciation & Amortization (CF) at $28000.0 in Q1 2026, $36000.0 in Q4 2025, and -$36000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Vor Biopharma | 627.54 Mn | 627.54 Mn | - | 28,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28,000.00 |
| Mar 31, 2026 | 28,000.00 |
| Dec 31, 2025 | 36,000.00 |
| Dec 31, 2025 | 36,000.00 |
| Sep 30, 2025 | -36,000.00 |
| Sep 30, 2025 | -36,000.00 |
| Jun 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 2.10 Mn |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Dec 31, 2024 | 800,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Sep 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 900,000.00 |
| Mar 31, 2024 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |
| Dec 31, 2023 | 900,000.00 |